Skip to main content

Direct Oral Anticoagulants in Sickle Cell Disease

· One min read
Hants Williams
Hants Williams
Healthcare Informatics Researcher

Abstract​

This research evaluates the safety profile of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism, focusing on bleeding incidence rates compared to traditional anticoagulation methods.

Publication Information​

Published in Blood (2017)
Volume: 130, Page: 978

Overview​

The study demonstrates the improved safety profile of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism, specifically highlighting the reduced incidence of bleeding complications.

[Full text available via Blood Journal]

Citation​

Patel, A., Williams, H., Baer, M. R., Zimrin, A. B., & Law, J. Y. (2017). Use of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism is associated with a significant decrease in incidence of bleeding. Blood, 130, 978.